Clinical Observation of S-1 Combined with Oxaliplatin or Paclitaxel on Advanced Gastric Cancer

Objective To observe the efficacy and adverse reaction of S-1 combined with oxaliplatin or paclitaxel in the treatment of advanced gastric cancer. Methods Ninety-one advanced gastric carcinoma patients were divided into two groups: SOX group(44 cases, S-1 plus oxaliplatin) and PS group (47 cases, S-1 plus paclitaxel). All cases took oral S-1, 80 mg/m2/day, d1~14; Moreover, SOX group took oxaliplatin, 130 mg /m2 on d1; PS group took paclitaxel, 80mg /m2 on d1, d8. 21 days was a cycle. Results RR in group SOX and PS were 36.4% and 40.4% (P=0.691), respectively. PFS was 5.0 months in SOX group and 5.4 months in PS group (P=0.45). OS was 13.5 months in SOX group and 16.4 months in PS group (P=0.76). Main adverse effects in two groups were neutropenia, gastrointestinal reaction and fatigue. The frequency of nausea and vomiting was 79.5% in SOX group and 51.1% in PS group(P＜0.05). Conclusion RR and OS of S-1 combined with SOX or PS were similar, with good curative effect and tolerable adverse reactions.